Cited by 172Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchBioinformatics and Genomic Networks

Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease

Open access
Beckmann, Noam D., Lin, Wei-Jye, Wang, Minghui, Cohain, Ariella T., Charney, Alexander W., Wang, Pei, Ma, Weiping, Wang, Ying-Chih +26 more·2020·Nature Communications

Abstract

Though discovered over 100 years ago, the molecular foundation of sporadic Alzheimer’s disease (AD) remains elusive. To better characterize the complex nature of AD, we constructed multiscale causal networks on a large human AD multi-omics dataset, integrating clinical features of AD, DNA variation, and gene- and protein-expression. These probabilistic causal models enabled detection, prioritization and replication of high-confidence master regulators of AD-associated networks, including the top predicted regulator, VGF. Overexpression of neuropeptide precursor VGF in 5xFAD mice partially rescued beta-amyloid-mediated memory impairment and neuropathology. Molecular validation of network predictions downstream of VGF was also achieved in this AD model, with significant enrichment for homologous genes identified as differentially expressed in 5xFAD brains overexpressing VGF. Our findings support a causal role for VGF in protecting against AD pathogenesis and progression.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-020-17405-z

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies using transgenic mouse models of AD have identified various mechanisms that lead to synaptic impairment in AD, including the accumulation of soluble amyloid-beta, Tau hyperphosphorylation, loss of VGF signaling, and glial state dysregulation.

    “For example, previous studies using transgenic mouse models of AD have identified various mechanisms that lead to synaptic impairment in AD, including the accumulation of soluble amyloid-beta, Tau hyperphosphorylation, loss of VGF signaling, and glial state dysregulation (e.g., the induction of disease-associated microglia and disease-associated astrocytes) (9, 23–30).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [26]Mirra SS The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease Neurology 1991 41 479 486 2011243
  2. [29]Hong GS Gene variations in GSTM3 are a risk factor for Alzheimer’s disease Neurobiol. Aging 2009 30 691 696 17904251
  3. [35]Zhang, B. & Zhu, J. Identification of key causal regulators in gene networks. In Proceedings of the World Congress on Engineering and Computer Science, Vol. 2 (Newswood Limited, Hong Kong, 2013).

Cited by

Sorted by citations

Authors
Beckmann, N. D., Lin, W.-J., Wang, M., Cohain, A. T., Charney, A. W., Wang, P., Ma, W., Wang, Y.-C., Jiang, C., Audrain, M., Comella, P. H., Fakira, A. K., Hariharan, S. P., Belbin, G. M., Girdhar, K., Levey, A. I., Seyfried, N. T., Dammer, E. B., Duong, D., Lah, J. J., Haure-Mirande, J.-V., Shackleton, B., Fanutza, T., Blitzer, R., Kenny, E., Zhu, J., Haroutunian, V., Katsel, P., Gandy, S., Tu, Z., Ehrlich, M. E., Zhang, B., Salton, S. R., & Schadt, E. E.
Affiliations
  • Icahn School of Medicine at Mount Sinai (US)
  • Sun Yat-sen University (CN)
  • Emory University (US)
  • Sema4 (United States) (US)
  • James J. Peters VA Medical Center (US)
Corresponding author
  • Salton, Stephen R.
  • Schadt, Eric E.
Venue
Nature Communications
Published
2020-08-07
Volume
11
Issue
1
Pages
3942-3942
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3048036301
Cited by
172
References
86
Citations by year
2026: 20 · 2025: 29 · 2024: 34 · 2023: 26 · 2022: 35 · 2021: 18 · 2020: 7 · 2019: 3
FWCI
13.09
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Alzheimer's Drug Discovery Foundation
  • BrightFocus Foundation
  • Icahn School of Medicine at Mount Sinai
  • Cure Alzheimer's Fund
  • National Natural Science Foundation of China (81972967, 2017B030314026)
  • Natural Science Foundation of Guangdong Province (2019A1515011754, 2017B030314026)
  • National Institutes of Health (5r01ag055501-05)
  • National Institute on Aging (R01AG057907, R01AG046170, U01AG046170, RF1AG054014, RF1AG057440, R01-AG055501, RF1AG062661, RF1AG057443, RF1AG059319, R01AG062355, U01AG046161, P50AG025688, R01AG067312, R01AG053960, P30AG066514)
  • National Institute of Mental Health (R21MH083496, R01MH086499, R33MH083496)
  • National Institute on Drug Abuse (HHSN271201300031C)
  • National Cancer Institute (U24CA210993)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK117504)
  • National Institute of Neurological Disorders and Stroke (P30NS055077)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
Alzheimer's disease, VGF, neuropeptide precursors, causal networks, probabilistic causal models, master regulators, multi-omics integration, 5xFAD mice, amyloid-beta, memory impairment, neuropathology, gene expression, DNA variation
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Animals, Brain, Disease Models, Animal, Female, Humans, Male, Mice, Transgenic, Nerve Growth Factors, Amyloid beta-Peptides, Gene Expression Profiling, Protein Interaction Mapping, Proteomics, Mice, Gene Regulatory Networks, Genome-Wide Association Study, Protein Interaction Maps, Datasets as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review